Phase II study with ifosfamide in advanced malignant melanoma

E. Negretti, L. Ferrari, V. Bonfante, E. Bajetta

Research output: Contribution to journalArticlepeer-review


Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma. The drug was administered at the dose of 3 g/m2 on days one and two every 3-weeks. Seven patients were not previously treated and 5 received only minimal prior chemotherapy. Visceral involvement was present in 9 patients, and the remaining 3 had only soft tissue lesions. No patient showed objective tumor response. Mild vomiting was observed in 75% of patients; alopecia occurred in all of them. No other major side effects were observed, in particular, myelotoxicity and urotoxicity. Lack of response advised us to discontinue patient accrual. Our data do not support a therapeutic role of ifosfamide at the given dose schedule in the treatment of metastatic malignant melanoma.

Original languageEnglish
Pages (from-to)163-165
Number of pages3
Issue number2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Phase II study with ifosfamide in advanced malignant melanoma'. Together they form a unique fingerprint.

Cite this